Immunosuppressive agents for treating IgA nephropathy-Reference-Cited by-同舟云学术

Immunosuppressive agents for treating IgA nephropathy

Published:2015-08-03 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Vecchio Mariacristina¹,Bonerba Bibiana²,Palmer Suetonia C³,Craig Jonathan C⁴⁵,Ruospo Marinella⁶⁷,Samuels Joshua A⁸,Molony Donald A⁹,Schena Francesco Paolo¹⁰,Strippoli Giovanni FM⁴⁵⁷¹⁰¹¹

Affiliation:

1. Danone Research; RD 128 Palaiseau Cedex France 91767

2. Diaverum; Via Solarino 1 Bari Italy 70124

3. University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140

4. The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006

5. The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145

6. Amedeo Avogadro University of Eastern Piedmont; Division of Nephrology and Transplantation, Department of Translational Medicine; Via Solaroli 17 Novara Italy 28100

7. Diaverum Medical Scientific Office; Lund Sweden

8. UT-Houston Health Science Center; Division of Pediatric Nephrology and Hypertension; 6431 Fannin Street, MSB 3-121 Houston TX USA 77030

9. UT-Houston Health Science Center; Internal Medicine; Division of Renal Diseases and Hypertension 64312 Fannin St Houston TX USA 77030

10. University of Bari; Department of Emergency and Organ Transplantation; Policlinico Piazza Giulio Cesare 11 Bari Italy 70124

11. Diaverum Academy; Bari Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference158 articles.

1. A controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy [abstract];Ballardie;Nephrology Dialysis Transplantation,1996

2. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy;Ballardie;Journal of the American Society of Nephrology,2002

3. Leflunomide plus low dose prednisone reduced urinary VCAM-1 level in progressive IgA nephropathy [abstract no: F-PO1851];Cao;Journal of the American Society of Nephrology,2008

4. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial;Frisch;Nephrology Dialysis Transplantation,2005

5. Mycophenolate mofetil vs placebo in patients at high risk for progressive IgA nephropathy: a double blind RCT [abstract no: SU-PO987];Frisch;Journal of the American Society of Nephrology,2003

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of losartan in childhood immunoglobulin A nephropathy: a prospective multicenter study;Childhood Kidney Diseases;2023-12-07

2. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial;The Lancet;2023-09

3. Innovative therapy for progressive IgA nephropathy with the oral encapsulated steroid preparation Nefecon®;Die Nephrologie;2023-03-01

4. A Core Outcome Set for Trials in Glomerular Disease;Clinical Journal of the American Society of Nephrology;2021-12-30

5. Long-term effects of immunosuppression treatment on IgA nephropathy: a systematic review and meta-analysis;Annals of Palliative Medicine;2021-11